# Gero

> Gero is a Singapore- and Palo Alto-based biotech company applying physics-informed AI to longitudinal human health data to find the root causes of aging and develop therapies for age-related diseases. Co-founded by physicist Peter Fedichev and entrepreneur Maxim Kholin, Gero has built a foundational model of human health trained on 100M+ medical records, and partners with major pharma including Pfizer and Chugai.

- **Founded:** 2018
- **Headquarters:** Singapore (with Palo Alto, California office)
- **Founders:** Peter Fedichev (Co-Founder & CEO), Maxim Kholin (Co-Founder & Chief Corporate Development Officer)
- **Team size:** ~140
- **Products:** Foundational Health Model, Target Discovery Platform, ProtoBind-Diff, Mobile health API
- **Notable:** Trained a foundational model on 100M+ longitudinal medical records., Secured deal of up to ~$250M with Chugai Pharmaceutical (July 2025)., Research collaboration with Pfizer on fibrotic disease.

## Products & services

- **Foundational Health Model** — Physics-informed AI trained on 100M+ longitudinal medical records that separates reversible disease from irreversible aging.
- **Target Discovery Platform** — AI-driven identification of therapeutic targets for age-related diseases, licensed to pharma partners.
- **ProtoBind-Diff** — 2025 generative AI model for structure-free drug design directly from protein sequences.
- **Mobile health API** — Earlier consumer-facing API for quantifying health changes from smartphone sensor data.

## Achievements

- Trained a foundational model on 100M+ longitudinal medical records.
- Secured deal of up to ~$250M with Chugai Pharmaceutical (July 2025).
- Research collaboration with Pfizer on fibrotic disease.
- Released ProtoBind-Diff (2025), an AI model for structure-free drug design.
- Raised ~$8.2M in disclosed funding across rounds.

## Latest updates

- **2025-07** — Announced joint research and license agreement with Chugai Pharmaceutical worth up to ~$250M for antibody therapies.
- **2025** — Released ProtoBind-Diff, a generative AI model for structure-free drug design from protein sequences.
- **2023-10** — Closed $6M Series A extension led by Melnichek Investments, with participation from VitaDAO.

## Links

- Website: https://gero.ai
- LinkedIn: https://www.linkedin.com/company/gero
- Twitter/X: https://twitter.com/hacking_aging
- Facebook: https://www.facebook.com/geroscience

---

Profile page: https://yespress.io/gero
Published by YesPress — https://yespress.io
Last updated: 2026-05-29